Combining traditional agents and biologics for the treatment of psoriasis.

Alan Menter, Jennifer Clay Cather

Journal: Seminars in cutaneous medicine and surgery 2005;24(1):37-45

PMID: 15900797

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Psoriasis patients deserve long-term control of their disease with optimal safety. Traditional agents (methotrexate, cyclosporine, retinoids, and photochemotherapy [PUVS]), although providing excellent short-term control, may produce acute or chronic toxicities, thus limiting their usage. Dermatologists are well versed in combination and rotational therapies for psoriasis, using these and other agents. With the advent of biologic therapies (three currently approved, and others pending), the potential for safer long-term psoriasis control is being realized. A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented.

Address: Baylor University Medical Center, Dallas, TX, USA.

DOI: 10.1016/j.sder.2005.01.002

Link outs

Free resources

Medical:

https://medlineplus.gov/psoriasis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Acitretin, Adalimumab, Alefacept, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Biological Products, Clinical Trials as Topic, Cyclosporine, Dermatologic Agents, Drug Therapy, Combination, Etanercept, Humans, Immunoglobulin G, Infliximab, Methotrexate, PUVA Therapy, Psoriasis, Receptors, Tumor Necrosis Factor, Recombinant Fusion Proteins